Urinary tract anti-inflammatory effect

The term “urinary tract anti-inflammatory effect” refers to a broad pharmacodynamic property, not a discrete molecular target. Multiple drugs, especially non-steroidal anti-inflammatory drugs (NSAIDs) and novel agents, can exert anti-inflammatory effects within the urinary tract by inhibiting specific pathways such as cyclooxygenase (COX) enzymes or by modulating inflammatory cytokines and cell recruitment, but these drugs do not share a single molecular target known as “urinary tract anti-inflammatory effect”[4][6]. Instead, several immune-related molecular targets have been researched for their role in urinary tract inflammation, such as NLRP3 inflammasome, Toll-like receptor 4 (TLR4), Caspase-1, STAT1, TNF, and others[4][5]. NSAIDs like diclofenac may be used clinically to reduce urinary tract inflammation, but carry increased risks, such as higher rates of complications (e.g., pyelonephritis), if used instead of antibiotics in bacterial infection[6]. In summary, this is not a valid molecular or receptor target, but a general pharmacological action mediated by multiple molecules and pathways.

by inhibiting specific pathways such as cyclooxygenase (COX) enzymes or by modulating inflammatory cytokines and cell recruitment